Literature DB >> 21794390

[Spanish Registry for Adverse Events of Biological Therapy in Rheumatic Diseases (BIOBADASER): state report, January 26 th, 2006].

Miguel Angel Descalzo1.   

Abstract

OBJECTIVE: BIOBADASER is a prospective registry of rheumatic patients treated with biological therapies, which aim is the analysis of long-term survival and safety of these agents. PATIENTS AND METHODS: As of January 26(th) 2006, 6,969 patients from 100 centers were included in BIOBADASER. In total, 8,321 treatments with biological therapies have been registered.
RESULTS: Treatment was discontinued in 2,351 (28%) occasions, mostly as a result of an adverse event (960;41%) or inefficacy (942;40%). A total of 2,503 adverse events were notified. Of these, the most frequent ones were infections (909;36%), followed by postinfusion reactions (500;20%), skin lesions (255;10%) and cardiovascular events (165;7%).
CONCLUSIONS: The analysis reassures us in the increased rate of infections with biological therapies. Neither the rates of neoplasm nor of cardiac failure are significantly increased with these therapies. Specific measures have proved useful in preventing the occurrence of defined events.
Copyright © 2007 Elsevier España S.L Barcelona. Published by Elsevier Espana. All rights reserved.

Entities:  

Year:  2008        PMID: 21794390     DOI: 10.1016/S1699-258X(07)73593-3

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  2 in total

1.  Haemophagocytic syndrome and paradoxical reaction to tuberculostatics after treatment with infliximab.

Authors:  Amelia Troncoso Mariño; Eva Campelo Sánchez; Noemí Martínez López de Castro; María Teresa Inaraja Bobo
Journal:  Pharm World Sci       Date:  2010-02-02

2.  Invasive Cryptococcosis and adalimumab treatment.

Authors:  Juan P Horcajada; Jose L Peña; Víctor M Martínez-Taboada; Trinitario Pina; Isabel Belaustegui; María Eliecer Cano; Daniel García-Palomo; M Carmen Fariñas
Journal:  Emerg Infect Dis       Date:  2007-06       Impact factor: 6.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.